Navigation Links
FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisor Board
Date:6/11/2012

SAN DIEGO, June 11, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, announced today that Dr. Prediman K. (PK) Shah has joined it's Scientific Advisory Board.

Dr. Shah is Professor at Cedar Cedars-Sinai Professorial Series, and Director of the Division of Cardiology. He also is the Director of the Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical Center where he leads several studies that focus on heart disease prevention and treatment. Dr. Shah holds the Shapell and Webb Family Chair in Clinical Cardiology at Cedars-Sinai. Dr. Shah has been Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) since 1992. Between 1992 and 2005, Dr. Shah and his colleagues conducted revolutionary research on mutant apo-A1 protein, called Apo-A1 Milano that produced a form of HDL that provided greater protection against atherosclerosis and vascular inflammation. In separate studies conducted, Dr. Shah found that a vaccine created from LDL significantly reduced plaque buildup in animals that had high cholesterol levels.

"We are very pleased Dr. Shah has joined FirstMark's advisory team, " said Thomas Silberg, President and CEO of GenWay Biotech. "His outstanding background in cardiovascular medicine, his focus on prevention, and his extensive experience in research will be a critical support as we continue to build clinical interest and application for FirstMark PREvent."

Dr. Shah joins the FirstMark Scientific Advisory Board that is composed of innovative and nationally recognized leaders in cardiology and research. Each of these individuals has made substantial contributions to the field of cardiology. The main focus of the Board is to provide guidance for further clinical development and validation of FirstMark's new cardiovascular test PREvent. PREvent is the first and only multiple biomarker blood test on the market that predicts near term (2-3 years) risk of myocardial infarction in patients with suspected or confirmed, insignificant or significant CAD. The test was recently launched, and its remarkable data is receiving a strong reception throughout cardiovascular medicine.

The FirstMark Scientific Advisory Board is comprised of prominent cardiologist and research scientists including:

George A. Beller, MD, MACC
Cardiologist, University of Virginia Health System
Past President of the American College of Cardiology
Past President of the Association of University Cardiologists
Past President of the Association of Professors of Cardiology

Stephen Epstein, MD
Executive Director of the Cardiovascular Research Institute (CRI), MedStar Health Research Institute
Clinical Professor of Medicine at the Georgetown University School of Medicine
Former Chief of the Cardiology Branch of the NHLBI at the National Institutes of Health in Bethesda, MD

Arshed Quyyumi, MD, FACC, FRCP
Tenured Professor of Medicine, Division of Cardiology, Emory University School of Medicine,
Co-Director, Emory Clinical Cardiovascular Research Institute

Prediman K. Shah, MD, FACC, FACP, FCCP
Director, Division of Cardiology at Cedars-Sinai Medical Center
Director, Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical Center
Shapell and Webb Family Chair in Clinical Cardiology
Professor, Cedars-Sinai Professorial Series

Sergey Sikora, PhD, MBA
Sr. Vice President,  FirstMark

Robert Wilensky, MD
Professor of Medicine at the Hospital of the University of Pennsylvania
Director, Interventional Cardiology Research

Peter Wilson, MD
Professor of Medicine, Emory Clinical Cardiovascular Research Institute
Professor of Public Health at the Rollins School of Public Health
Director of Epidemiology and Genomic Medicine, Atlanta VA Medical Center

For more information about FirstMark PREvent and the Scientific Advisory Board, visit FirstMarkPREvent.com

FirstMark PREvent
The study revealed superior cardiac risk information by identifying the top 5% of CAD at the highest risk of MI with a hazard ratio of 5.5. The data showed an annual average of 18.2% of significant CAD patients with all three biomarkers elevated experienced a myocardial infarction or death, compared to only 2.45% of significant CAD patients with all biomarkers normal. The multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk from low risk subjects.

About FirstMark
FirstMark is a division of GenWay Biotech, Inc. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area.

6777 Nancy Ridge Drive, San Diego, CA 92121     |     P: 858.458.0866     |     F: 858.458.0833

Media Contact: Deborah Moore GenWay Biotech, Inc., 858-458-0866, dmoore@genwaybio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 


'/>"/>
SOURCE GenWay Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
2. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
3. EMBO welcomes 55 leading life scientists as members
4. Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award
5. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
6. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
7. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
8. U of Alberta researcher steps closer to understand autoimmune diseases
9. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
10. UNH researchers find African farmers need better climate change data to improve farming practices
11. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
(Date:3/21/2016)... Massachusetts , March 22, 2016 ... facial recognition with passcodes for superior security   ... ), a leading provider of secure digital communications services, ... their biometric technology and offer enterprise customers, particularly those ... secure facial recognition and voice authentication within a mobile ...
(Date:3/15/2016)... Yissum Research Development Company of the ... the Hebrew University, announced today the formation of ... various human biological indicators. Neteera Technologies has completed its ... investors. ... electromagnetic emissions from sweat ducts, enables reliable and speedy ...
Breaking Biology News(10 mins):
(Date:5/20/2016)... ... ... Korean researchers say Manumycin A triggers apoptosis, or natural cell death, in malignant ... Surviving Mesothelioma has just posted an article on the new study. Click here ... study on the fact the Manumycin A, a derivative of Streptomyces parvulus, is known ...
(Date:5/19/2016)... ... May 19, 2016 , ... ... (CRO) has welcomed Abu Siddiqui as Director, Large Molecule & Biomarker Bioanalysis. , ... vaccine and translational biomarker discovery studies for preclinical and clinical safety programs. “We’ve ...
(Date:5/18/2016)... , May 18, 2016 The Biotech ... does not mean that there are no opportunities ahead. Today, ... Inc. (NASDAQ: THLD ), Seattle Genetics Inc. (NASDAQ: ... ), and Ophthotech Corp. (NASDAQ: OPHT ). Sign ... at: http://www.activewallst.com/ Threshold Pharmaceuticals ...
(Date:5/17/2016)... , May 18, 2016 ... 2.0 prefilled pen following approval by EMA, the European ... leading science and technology company, the new pen version ... an increased level of confidence to patients during use. ... GONAL-f® prefilled pen easier to handle with a larger ...
Breaking Biology Technology: